Increased frequency of GM-CSF secreting PBMC in patients with active systemic lupus erythematosus can be reduced by immunoadsorption

Lupus

Volumn 13, Issue 4, 2004, Pages 257-262

  Willeke, Peter ^a   Schluter B ^a   Schotte, H ^a   Erren, M ^a   Mickholz, E ^a   Domschke, W ^a   Gaubitz, M ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

ELISPOT; GM CSF; Immunoadsorption; Systemic lupus erythematosus

Indexed keywords

CD4 ANTIGEN; CD71 ANTIGEN; CD86 ANTIGEN; CELL MARKER; DNA ANTIBODY; DOUBLE STRANDED DNA; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELL COUNT; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOADSORPTION; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSORBENT TECHNIQUES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; MONOCYTES;

EID: 2442460939     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu1009oa     Document Type: Article

References (30)

1. al-Janadi M, Raziuddin S. B cell hyperactivity is a function of T cell derived cytokines in systemic lupus erythematosus. J Rheumatol 1993; 20: 1885-1891.
2. Hamilton JA. GM-CSF in inflammation and autoimmunity. Trends Immunol 2002; 23: 403-408.
3. Ibelgaufts H. Granulocyte-macrophage colony-stimulating factor. In: Ibelgaufts H (ed) Dictionary of Cytokines. Wiley: Basel, 1994,290-296.
4. Kruger M, Van Gool S, Peng XH, Coorevits L, Casteels-Van Daele M, Ceuppens JL. Production of granulocyte-macrophage colony-stimulating factor by T cells is regulated by B7 and IL-1 beta. Immunology 1996; 88: 49-54.
5. Hamilton JA. Colony stimulating factors, cytokines and monocyte-macrophages - some controversies. Immunol Today 1993; 14: 18-24.
6. Campbell IK, Rich MJ, Bischof RJ, Dunn AR, Grail D, Hamilton JA. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol 1998; 161: 3639-3644.
7. Braun N, Erley C, Klein R, Kotter I, Saal J, Risler T. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrol Dial Transplant 2000; 15: 1367-1372.
8. Gaubitz M, Seidel M, Kummer S et al. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. J Autoimmun 1998; 11: 495-501.
9. Sun KH, Yu CL, Tang SJ, Sun GH. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis. Immunology 2000; 99: 352-360.
10. Neng LK, Leung JC, Bik LK, Li PK, Lai CK. Anti-DNA autoantibodies stimulate the release of interleukin-1 and interleukin-6 from endothelial cells. J Pathol 1996; 178: 451-457.
11. Braun N, Risler T. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther Apher 1999; 3: 240-245.
12. Willeke P, Schotte H, Erren M, et al. Concomitant reduction of disease activity and IL-10 secreting peripheral blood mononuclear cells during immunoadsorption in patients with active systemic lupus erythematosus. Cell Mol Biol 2002; 48: 323-329.
13. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
14. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
15. Vaquerano JE, Peng M, Chang JW, Zhou YM, Leong SP. Digital quantification of the enzyme-linked immunospot (ELISPOT). Biotechniques 1998; 25: 830-834.
16. Fiehn C, Wermann M, Pezzutto A, Hufner M, Heilig B. Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy. Z Rheumatol 1992; 51: 121-126.
17. Starkebaum G. Chronic neutropenia associated with autoimmune disease. Semin Hematol 2002; 39: 121-127.
18. Liu MF, Li JS, Weng TH, Lei HY. Differential expression and modulation of costimulatory molecules CD80 and CD86 on monocytes from patients with systemic lupus erythematosus. Scand J Immunol 1999; 49: 82-87.
19. Sfikakis PP, Via CS. Expression of CD28, CTLA4, CD80, and CD86 molecules in patients with autoimmune rheumatic diseases: implications for immunotherapy. Clin Immunol Immunopathol 1997; 83: 195-198.
20. Shirakawa F, Yamashita U, Suzuki H. Decrease in HLA-DR-positive monocytes in patients with systemic lupus erythematosus (SLE). J Immunol 1985; 134: 3560-3562.
21. Steinbach F, Henke F, Krause B, Thiele B, Burmester GR, Hiepe F. Monocytes from systemic lupus erythematous patients are severely altered in phenotype and lineage flexibility. Ann Rheum Dis 2000; 59: 283-288.
22. Döcke WD, Reinke P, Taffa G et al. An immune monitoring program for the management of immunosuppressive therapy in the early phase after transplantation. Transplantationsmedizin 1994; 6: 13-28.
23. Hagiwara E, Gourley MF, Lee S, Klinman DK. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996; 39: 379-385.
24. Kox WJ, Volk T, Kox SN, Volk HD. Immunomodulatory therapies in sepsis. Intens Care Med 2000; 26(Suppl): 124-128.
25. Llorente L, Zou W, Levy Y et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839-844.
26. Hayashi M, Dorf ME, Abromson-Leeman S. Granulocyte-macrophage colony stimulating factor inhibits class II major histocompatibility complex expression and antigen presentation by microglia. J Neuroimmunol 1993; 48: 23-32.
27. May WS Jr, Cuatrecasas P. Transferrin receptor: its biological significance. J Membr Biol 1985; 88: 205-215.
28. Rastellini C, Braun M, Li X et al. Prolongation of pancreatic islet graft survival by blocking transferrin receptor (CD71). Transplant Proc 2001; 33: 518-519.
29. Vallin H, Perers A, Alm GV, Ronnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol 1999; 163: 6306-6313.
30. Portales-Perez D, Alarcon-Segovia D, Llorente L et al. Penetrating anti-DNA monoclonal antibodies induce activation of human peripheral blood mononuclear cells. J Autoimmun 1998; 11: 563-571.